Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

Novel Therapy Lands Speedy Approval for Wart-Like Airway Disease

(MedPage Today) -- The FDA granted accelerated approval to doruxapapogene ralaplasmid and lalikinogene sifuplasmid (Voceryq) to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP), the...

Precigen craters on Inovio Voceryq immunotherapy approval

Precigen stock sank after FDA approved Inovio's rival recurrent respiratory papillomatosis therapy Voceryq. Read more here.

Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, formerly known as INO-3107, as a nonsurgical treatment intended to reduce the frequency of surgeries in adults with recurrent respiratory papillomatosis, or RRP. VOCERYQ is the co

Inovio stock rises 2.5-fold on plasmid DNA drug approval

Inovio Pharma's plasmid DNA-based Voceryq has become the second drug approved in the US for adults with recurrent respiratory papillomatosis.

New DNA-based therapy offers adults with recurrent HPV airway disease an alternative to repeated surgeries

The FDA granted accelerated approval to Inovio's Voceryq for adults with recurrent respiratory papillomatosis, a rare HPV-related airway disease requiring repeated surgeries.

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgeryVOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP: HPV-6 and HPV-11INOVIO…